SENTRI:用于放射性核素注射的单粒子能量转换器,以实现个性化靶向放射性核素癌症治疗
本研究开发了一种可直接植入肿瘤的0.27 mm³单片硅芯片β粒子敏感剂量计,在小鼠前列腺癌模型中使用177Lu-PSMA-617验证其性能。系统检测范围为0.013至8.95 MBq/mL,测量数据与177Lu-PSMA-617活度高度成比例(R² > 0.99),体内测量结果与SPECT/CT结果在可接受误差(±1.5%ID/mL)内一致。
要点
- 植入式0.27 mm³硅芯片剂量计可实时检测肿瘤和危及器官的剂量沉积。
- 检测范围0.013至8.95 MBq/mL,测量数据与177Lu-PSMA-617活度高度成比例(R² > 0.99)。
- 体内测量结果与SPECT/CT结果在±1.5%ID/mL误差内一致。
核心结论
- 鉴于靶向放射性核素治疗在前列腺癌临床应用的近期进展,所提出的系统已在前列腺癌小鼠模型中使用177Lu-PSMA-617完成验证。
研究设计与样本
- 研究将PC3-PIP(PSMA+)和PC3-flu(PSMA-)细胞系分别注射到小鼠左右侧腹,并将0.27 mm³单片硅芯片剂量计植入每个肿瘤。
- 剂量计由1 μm²最小尺寸二极管阵列(64×64)组成,集成信号放大器、缓冲器和片上存储器。
- 在177Lu-PSMA-617注射后5个不同时间点(0-2小时、7-9小时、12-14小时、24-26小时和48-50小时)测量活度,并用单光子发射计算机断层扫描/计算机断层扫描验证测量数据。
主要发现
- 系统检测范围为0.013至8.95 MBq/mL,能够实时检测高肿瘤摄取以及危及器官中的低剂量。
- 测量数据与177Lu-PSMA-617活度高度成比例(R² > 0.99)。
- 体内测量数据与单光子发射计算机断层扫描/计算机断层扫描结果在可接受误差(±1.5%ID/mL)内一致。
关键数值与推荐
- 剂量计检测范围为0.013至8.95 MBq/mL。
- 测量数据与177Lu-PSMA-617活度的决定系数R² > 0.99。
- 体内测量数据与SPECT/CT结果的误差在±1.5%ID/mL以内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeted radionuclide therapy (TRT), whereby a tumor-targeted molecule is linked to a therapeutic beta- or alpha-emitting radioactive nuclide, is a promising treatment modality for patients with metastatic cancer, delivering radiation systemically. However, patients still progress due to suboptimal dosing, driven by the large patient-to-patient variability. Therefore, the ability to continuously monitor the real-time dose deposition in tumors and organs at risk provides an additional dimension of information during clinical trials that can enable insights into better strategies to personalize TRT. METHODS AND MATERIALS: Here, we present a single beta-particle sensitive dosimeter consisting of a 0.27-mm3 monolithic silicon chiplet directly implanted into the tumor. To maximize the sensitivity and have enough detection area, minimum-size diodes (1 μm2) are arrayed in 64 × 64. Signal amplifiers, buffers, and on-chip memories are all integrated in the chip. For verification, PC3-PIP (prostate-specific membrane antigen [PSMA]+) and PC3-flu (PSMA-) cell lines are injected into the left and right flanks of the mice, respectively. The devices are inserted into each tumor and measure activities at 5 different time points (0-2 hours, 7-9 hours, 12-14 hours, 24-26 hours, and 48-50 hours) after 177Lu-PSMA-617 injections. Single-photon emission computed tomography/computed tomography scans are used to verify measured data. RESULTS: With a wide detection range from 0.013 to 8.95 MBq/mL, the system is capable of detecting high tumor uptake as well as low doses delivered to organs at risk in real time. The measurement data are highly proportional (R2 > 0.99) to the 177Lu-PSMA-617 activity. The in vivo measurement data agree well with the single-photon emission computed tomography/computed tomography results within acceptable errors (±1.5%ID/mL). CONCLUSIONS: Given the recent advances in clinical use of TRT in prostate cancer, the proposed system is verified in a prostate cancer mouse model using 177Lu-PSMA-617.
引用
- Lee K, Lall R, Chopra S, et al. SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 38122990. doi:10.1016/j.ijrobp.2023.11.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。